Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this immunotherapy in this patient group, led by UCL and UCLH researchers. The ALARIC trial, which was developed within the UK Myeloma Research Alliance and is supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre, aims to treat at least 12 patients at UCLH over the next two years and will also